<DOC>
	<DOCNO>NCT02114268</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics extend half-life anti-respiratory syncytial virus ( RSV ) monoclonal antibody compare placebo administer healthy adult participant .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety , Tolerability , Pharmacokinetics MEDI8897 Healthy Adults</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled , dose-escalation study evaluate safety , tolerability pharmacokinetics MEDI8897 compare placebo administer healthy adult participant . There 136 participant randomize receive MEDI8897 placebo one site . Investigational product deliver intravenously ( IV ) 3 cohort intramuscularly ( IM ) 2 cohort . 4 different dose level investigational product evaluate across 5 cohort . Participants follow approximately 1 year .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Key Age 18 49 year good health history , physical exam , labs Weight great equal ( &gt; = ) 45 kilogram ( kg ) less equal ( &lt; = ) 110 kg Screening Written informed consent prior perform protocol related procedure , include Screening evaluation Ability complete Followup period 360 day Key Acute illness include fever &gt; = 99.5 Fahrenheit ( Â°F ) day dose Any drug therapy within 7 day prior Day 1 ( except contraceptive ) Receipt investigational drug therapy within 120 day prior investigational product dose 360 day investigational product dose Previous receipt monoclonal antibody ( mAb ) Pregnant nursing mother Concurrent enrollment another interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Respiratory Syncytial Virus , RSV</keyword>
</DOC>